I----ntional Application No /GB2004/050025

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/495 A61K31/704 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} & \mbox{A61P} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ

C. DOCUM	INTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	WO 00/69441 A (LOPEZ LAZARO LUIS ; JIMENO JOSE (ES); PHARMA MAR SA (ES); GUZMAN CECIL) 23 November 2000 (2000-11-23)	1,3-5, 14-18
Y	cited in the application page 8, lines 9-13,25 page 13, lines 13-17; claims 1,16,9,10	2,6-13
X	WO 03/039571 A1 (PHARMAMAR S.A; JIMENO, JOSE; RUIZ CASADO, ANA; LOPEZ LAZARO, LUIS; ROW) 15 May 2003 (2003-05-15)	1,3, 14-18
Υ	page 11, paragraph 2; claims 1,3,6,13-15,17	2,6-13
X	WO 02/36135 A (PHARMA MAR SA; GESCHER ANDREAS (GB); GIAVAZZI RAFAELLA (IT); INCALCI) 10 May 2002 (2002-05-10) cited in the application	18
Υ	claims 1,4,6; example 7	1–17

ł				
X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.			
Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance E* earlier document but published on or after the International filling date L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means P* document published prior to the international filling date but later than the priority date claimed	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family 			
Date of the actual completion of the international search 27 January 2005	Date of mailing of the international search report 14/02/2005			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Allnutt, S			

'GB2004/050025

		6B2004/050025
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TAKAHASHI N ET AL: "Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. OCT 2001, vol. 7, no. 10, October 2001 (2001-10), pages 3251-3257, XP002314514 ISSN: 1078-0432 page 3251, paragraph 3-12 page 3256, column 1, lines 26-28	1-18
Υ .	VAN KESTEREN CH ET AL: "Yondelis(R) (trabectedin, ET-743): The development of an anticancer agent of marine origin." ANTI-CANCER DRUGS, vol. 14, no. 7, August 2003 (2003-08), pages 487-502, XP009042983 ISSN: 0959-4973 page 494, column 2, paragraph 4 page 495, column 1, lines 10,11, paragraph 4	1-18
	page 497, column 1, paragraph 1 page 500, column 1, paragraph 3	
Y	VAN KESTEREN CHARLOTTE ET AL: "Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study" ANTI-CANCER DRUGS, vol. 13, no. 4, April 2002 (2002-04), pages 381-393, XP009042982 ISSN: 0959-4973 page 381, column 1, lines 4-6 page 383, lines 23-27 page 388, column 2, lines 9-16 page 392, column 1, paragraph 2	1-18
Υ	LAVERDIERE CAROLINE ET AL: "Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma." CANCER, vol. 98, no. 4, 15 August 2003 (2003-08-15), pages 832-840, XP002314512 ISSN: 0008-543X page 833, column 2, lines 40-3 page 835, column 2, lines 29-32 page 838, column 1, lines 5-8	1-18

'----ational Application No ----GB2004/050025

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ° GIANNI L; GRASSELLI G, DE BRAUD F ETAL: 1,3-8, P,X 14-18 "Definition of the least toxic sequence and optimal therapeutic dose of Yondelis in combination with doxorubicin in patients with untreated metastatic soft tissue sarcomas" CLINICAL CANCER RESEARCH, vol. 9, no. 16, 1 December 2003 (2003-12-01), page 6081S, XP001205017 the whole document

	E
	5
	ř n c
	~
1	1

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 1-15 because they relate to subject matter not required to be searched by this Authority, namely: Although claims 1-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: .
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

BEST AVAILABLE CO

INTERNATIONAL SEARCH REPORT

'---ational Application No /GB2004/050025

Patent document cited in search report		Publication date	-"	Patent family member(s)		Publication date
WO 0069441	A	23-11-2000	AU	777417	R2	14-10-2004
WU UUU9441	^	23 11 2000	AU	4597500		05-12-2000
			BG	106171		28-06-2002
						04-06-2002
			BR	0010531		
			CA	2373794		23-11-2000
			CN	1360503		24-07-2002
			CZ	20014081		13-11-2002
			EP	1176964		06-02-2002
			WO	0069441		23-11-2000
			HU	0201187	A2	28-09-2002
			JP	2002544231	T	24-12-2002
			MX	PA01011562	Α	30-07-2002
			NO	20015516		11-01-2002
			NZ	515423		30-04-2004
			PL	352931		22-09-2003
			SK	16442001		05-03-2002
			TR	200103819		22-04-2002
			NZ	529801		19-12-2003
WO 03039571	A1	15-05-2003	BR	0213424		14-12-2004
•			CA	2462502		15-05-2003
			EP	1435988		14-07-2004
			US	2005004018	A1	06-01-2005
WO 0236135	A	10-05-2002	AU	1249902	Α	15-05-2002
			BG	107843		30-06-2004
			BR	0115162	Α	21-10-2003
			CA	2428160	A1	10-05-2002
			CN	1486193	T	31-03-2004
			CZ	20031327		12-11-2003
			ĔΡ	1365808		03-12-2003
		÷	WO	0236135		10-05-2002
			HÜ	0400648		28-06-2004
			JP	2004517056	T	10-06-2004
			NO	20032027	•	04-07-2003
						24-12-2004
			117	M 7 M 7 Z I I		
			NZ	525730		
			PL	361389	A1	04-10-2004
					A1 A3	